XTRX.CN - Adastra Holdings Ltd.
| Previous Close | 0.4200 |
| Open | 0.4400 |
| Bid | 0.4200 x N/A |
| Ask | 0.4400 x N/A |
| Day's Range | 0.4200 - 0.4400 |
| 52 Week Range | 0.1050 - 2.0000 |
| Volume | |
| Avg. Volume | 90,144 |
| Market Cap | 23.508M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Adastra Holdings Reports First Quarter Results; Demonstrating Record Quarterly Gross Revenues of $9.5M
Adastra Holdings Ltd. (CSE:XTRX) (FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian concentrates brands, with a focus on product innovation and commercialization for adult-use and medical markets, is pleased to report financial results for the three months ended March 31, 2023.
- ACCESSWIRE
Adastra Holdings Reports FY2022 Results; Demonstrating A Second Year of Record Revenue
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian concentrates brands, with a focus on product innovation and commercialization for adult-use and medical markets, is pleased to report financial results for the fourth quarter and the year ended December 31, 2022.
- ACCESSWIRE
Adastra Accelerates Growth; 152% Increase in Shipment Volume
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, announces record shipment volume for January and February 2023 and plans to further accelerate product and brand presence across Canada.
- ACCESSWIRE
Adastra to Defend Lawsuit
/ Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company") a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, advises that it has been served with a civil claim filed in the Supreme Court of British Columbia pursuant to the Class Proceedings Act, R.S.B.C. 1996, c.
- ACCESSWIRE
Adastra Labs Clarifies and Retracts Certain Disclosure Related to its Receipt of Health Canada Approval for the Amendment to Include Cocaine Under its Controlled Substances Licence
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, retracts the statements in its news release dated February 22, 2023.
- ACCESSWIRE
Adastra Labs Receives Health Canada Approval for the Amendment to Include Cocaine Under its Controlled Substances Dealer’s License
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to announce that Adastra Labs received approval from Health Canada on February 17, 2023, for its amendment to include cocaine as a substance that the Company can legally possess, produce, sell and distribute.
- ACCESSWIRE
Leadership Update: Adastra Appoints Lachlan McLeod as CFO
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company and producer of two top Canadian concentrate brands, with a focus on processing, adult-use and medical sales, organoleptic and analytical testing, today announced that Lachlan McLeod, CPA of Fehr & Associates, has been appointed Chief Financial Officer.
- ACCESSWIRE
Adastra Completes Transaction to Terminate Legacy Supply Agreement, Bringing Phyto Extractions Brand 100% In-House
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP)("Adastra" or the "Company") a leading cannabis company and producer of two top Canadian concentrate brands, with a focus on processing, adult-use and medical sales, organoleptic and analytical testing, announces the termination of a legacy supply agreement for the Company's Phyto Extractions Brand ("Phyto").
- ACCESSWIRE
Adastra Holdings Reports Third Quarter Results; Demonstrating Third Consecutive Quarter of Record Revenue
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company and producer of two top Canadian concentrates brands, with a focus on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to report financial results for the three and nine months ended September 30, 2022.
ACCESSWIREAdastra Receives Controlled Substances Dealer's License
Adastra Holdings Ltd. (CSE:XTRX) (FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to announce that the Company has received its Controlled Drug and Substances Dealer's License ("Dealer's License") on August 24, 2022.
- ACCESSWIRE
Adastra Signs Option to Terminate Legacy Supply Agreement to Streamline Operations and Maximize Revenue
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company") is pleased to announce it has entered into an agreement effective August 30, 2022, with a third party (the "Agreement"), whereby Adastra has the right and option to terminate an exclusive amended license agreement dated December 4, 2020 (the "Phyto License Agreement") between the third party and 1204581 B.C.
- ACCESSWIRE
Adastra Holdings Reports Record Second Quarter Results; Momentum Accelerating in Second Half of the Year
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, is pleased to report financial results for the three and six months ended June 30, 2022.
- ACCESSWIRE
Adastra Expands Market Footprint Through Receipt of Medical Sales License from Health Canada
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP)("Adastra" or the "Company"), a leading cannabis company focused on processing, product development, sales, organoleptic testing and analytical testing, is pleased to announce it has received its Medical Sales License from Health Canada which now authorizes Adastra to sell cannabinoid-containing products that are formulated for and distributed to the medical cannabis market.
CNW GroupAdastra Holdings Continues to Execute on Transformational Strategy; New Product Launches; Outlines Growth Strategy
Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, sales, organoleptic testing and analytical testing, is pleased to provide the Company's shareholders with a corporate update from Michael Forbes, Director and Chief Executive Officer of Adastra: